IBSA
Clinically Driven Innovation with Global Reach
Known for their Profhilo® product lines, IBSA Derma leverages the pharmaceutical heritage of IBSA Group—established in Switzerland in 1945—and applies it to the development of hyaluronic acid-based medical devices used in aesthetic and dermatological practice. With operations in over 80 countries, IBSA Derma combines global experience with a strong foundation in clinical research and biotechnological innovation.
The company maintains full control over its production process, from the biofermentation of raw hyaluronic acid to final manufacturing in pre-filled syringes. This integrated approach ensures high standards of quality, consistency, and traceability. With all research and production conducted in Italy, IBSA Derma provides health care professionals with reliable, scientifically developed solutions tailored to clinical needs.
Healthcare professionals should refer to the Instructions for Use (IFU) leaflet for further information regarding these products.
Patient Information Leaflets (PIL) are available for reference.
IBSA Derma’s NAHYCO® Technology
NAHYCO® Technology is a patented process developed by IBSA Derma that combines high- and low-molecular-weight hyaluronic acid into a hybrid complex. This process does not involve chemical cross-linking agents and is designed to support the physical and biochemical properties of hyaluronic acid in clinical applications.
Used in a range of IBSA Derma products, NAHYCO® Technology allows for a unique formulation profile that maintains the integrity of hyaluronic acid. For health care professionals, this offers an option for managing aesthetic consultations where hyaluronic acid-based treatments are considered appropriate.
These products should be administered in line with clinical expertise, relevant training, and individual patient needs, always adhering to current regulatory requirements and professional standards.